Personal information

Other IDs

Scopus Author ID: 15736473100
ResearcherID: B-9959-2017

Activities

Collapse all

Employment (1)

Charles University, First Faculty of Medicine: Prague, CZ

teacher (Department of Oncology)
Employment
Source: Self-asserted source
Eva Sedlackova

Works (50 of 61)

Items per page:
Page 1 of 2

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study

Endocrine-Related Cancer
2016 | Journal article
DOI: 10.1530/ERC-15-0490
EID:

2-s2.0-84963958033
Contributors: Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčkova, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier
grade
Preferred source (of 2)‎

ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443172
EID:

2-s2.0-84953774685
Contributors: Garcia-Carbonero, R.; Sorbye, H.; Baudin, E.; Raymond, E.; Wiedenmann, B.; Niederle, B.; Sedlackova, E.; Toumpanakis, C.; Anlauf, M.; Cwikla, J.B. et al.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier
grade
Preferred source (of 2)‎

ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443165
WOSUID:

WOS:000374511400005
Contributors: Pape, U. -F.; Niederle, B.; Costa, F.; Gross, D.; Kelestimur, F.; Kianmanesh, R.; Knigge, U.; Oberg, K.; Pavel, M.; Perren, A. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443166
WOSUID:

WOS:000374511400004
Contributors: Ramage, J. K.; De Herder, W. W.; Delle Fave, G.; Ferolla, P.; Ferone, D.; Ito, T.; Ruszniewski, P.; Sundin, A.; Weber, W.; Zheng-Pei, Z. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443168
WOSUID:

WOS:000374511400002
Contributors: Delle Fave, G.; O'Toole, D.; Sundin, A.; Taal, B.; Ferolla, P.; Ramage, J. K.; Ferone, D.; Ito, T.; Weber, W.; Zheng-Pei, Z. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443170
WOSUID:

WOS:000374511400003
Contributors: Niederle, B.; Pape, U. -F.; Costa, F.; Gross, D.; Kelestimur, F.; Knigge, U.; Oberg, K.; Pavel, M.; Perren, A.; Toumpanakis, C. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443167
WOSUID:

WOS:000374511400007
Contributors: Pavel, M.; O'Toole, D.; Costa, F.; Capdevila, J.; Gross, D.; Kianmanesh, R.; Krenning, E.; Knigge, U.; Salazar, R.; Pape, U. -F. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Neuroendocrinology
2016 | Journal article
DOI: 10.1159/000443171
WOSUID:

WOS:000374511400006
Contributors: Falconi, M.; Eriksson, B.; Kaltsas, G.; Bartsch, D. K.; Capdevila, J.; Caplin, M.; Kos-Kudla, B.; Kwekkeboom, D.; Rindi, G.; Kloeppel, G. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Growing incidence of pancreatic neuroendocrine tumours (PNET) in Czech Republic

Annals of Oncology
2016 | Journal article
WOSUID:

WOS:000379756200238
Contributors: Barkmanova, J.; Zvolsky, M.; Vtek, P.; Sedlackova, E.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide Depot/Autogel in Intestinal and Pancreatic Neuroendocrine Tumors According to Body Mass Index: Subgroup Analyses From the CLARINET Study

Pancreas
2016 | Journal article
WOSUID:

WOS:000370956600080
Contributors: Wolin, Edward M.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Merkel Cell Carcinoma - Epidemiology Data from the Czech National Cancer Registry

Neuroendocrinology
2016 | Journal article
WOSUID:

WOS:000386481600036
Contributors: Bajciova, V.; Barkmanova, J.; Zvolsky, M.; Sedlackova, E.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Multivariate Analysis of Progression-Free Survival in the CLARINET Study of Lanreotide Autogel/Depot vs Placebo Identifies Prognostic Factors in Neuroendocrine Tumors

Pancreas
2016 | Journal article
WOSUID:

WOS:000370956600082
Contributors: Wolin, Edward M.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study

Pancreas
2015 | Journal article
WOSUID:

WOS:000349769400044
Contributors: Caplin, Martyn E.; Phan, Alexandria T.; Ruszniewski, Philippe; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wall, Lucy; Rindi, Guido et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-) NET: Update from the CLARINET Open-Label Extension (OLE) Study

Neuroendocrinology
2015 | Journal article
WOSUID:

WOS:000361683500124
Contributors: Caplin, M.; Pavel, M.; Cwikla, J. B.; Phan, A. T.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wolin, E. M.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study

Neuroendocrinology
2015 | Journal article
WOSUID:

WOS:000361683500126
Contributors: Caplin, M.; Pavel, M.; Cwikla, J. B.; Phan, A. T.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wolin, E. M.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000356883800231
Contributors: Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000356883800365
Contributors: Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-)NETs: Post Hoc Analyses from the CLARINET Study

Neuroendocrinology
2015 | Journal article
WOSUID:

WOS:000361683500125
Contributors: Caplin, M.; Pavel, M.; Cwikla, J. B.; Phan, A. T.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wolin, E. M.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Ki 67 and/or Mitotic Count in the Czech Neuroendocrine Tumour Registry

Pancreas
2015 | Journal article
WOSUID:

WOS:000349769400065
Contributors: Sedlackova, Eva; Barkmanova, Jaroslava; Honova, Hana; Tomasek, Jiri; Siffnerova, Hana; Mandys, Vaclav; Maluskova, Denisa; Muzik, Jan
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Kolorektální karcinom

Onkologie (Czech Republic)
2015 | Journal article
EID:

2-s2.0-84953395010
Contributors: Sedláčková, E.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier

Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036902948
Contributors: Wolin, Edward M.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036900942
Contributors: Dasari, A.; Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036902944
Contributors: Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged <= 65 vs. > 65 years: Subgroup analyses from the CLARINET study.

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036902943
Contributors: Dasari, A.; Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours

European Journal of Cancer
2015 | Journal article
WOSUID:

WOS:000361887402171
Contributors: Wolin, E.; Caplin, M.; Pavel, M.; Cwikla, J.; Phan, A.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Podávání kontinuálních infuzí cytostatik pomocí elastomerickỳch infuzorů

Clinical Oncology
2015 | Journal article
EID:

2-s2.0-84945282353
Contributors: Sedláčková, E.; Netíková, I.; Dlouhá, Z.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier

Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036902946
Contributors: Wolin, Edward M.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel

European Journal of Cancer
2015 | Journal article
WOSUID:

WOS:000361887402128
Contributors: Grenader, T.; Ruszniewski, P.; Pavel, M.; Cwikla, J.; Phan, A.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wolin, E.; Capdevila, J. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

Annals of Oncology
2015 | Journal article
DOI: 10.1093/annonc/mdv041
EID:

2-s2.0-84941651569
Contributors: Caplin, M.E.; Baudin, E.; Ferolla, P.; Filosso, P.; Garcia-Yuste, M.; Lim, E.; Oberg, K.; Pelosi, G.; Perren, A.; Rossi, R.E. et al.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier
grade
Preferred source (of 2)‎

Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study

Pancreas
2015 | Journal article
WOSUID:

WOS:000349769400063
Contributors: Ruszniewski, Philippe; Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wall, Lucy; Rindi, Guido et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours

European Journal of Cancer
2015 | Journal article
WOSUID:

WOS:000361887402167
Contributors: Phan, A.; Caplin, M.; Pavel, M.; Cwikla, J.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).

Journal of Clinical Oncology
2015 | Journal article
WOSUID:

WOS:000358036902947
Contributors: Phan, Alexandria T.; Caplin, Martyn E.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M.; Capdevila, Jaume; Wall, Lucy et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Co nového v lécbe metastatického kolorektálního karcinomu po cervnovém Congress on Gastrointestinal Cancer (WCGIC) v Barcelone 2014

Onkologie (Czech Republic)
2014 | Journal article
EID:

2-s2.0-84922709517
Contributors: Sedlácková, E
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier

COMBINED ORAL METRONOMIC AND BIODIFFERENTIATING ANTI-ANGIOGENIC THERAPY WITH GASTROENTERO-PANCREATIC PATIENTS WITH NEUROENDOCRINE TUMORS (GEP-NETS)

Anticancer Research
2014 | Journal article
WOSUID:

WOS:000344961300124
Contributors: Holubec, L.; Finek, J.; Fiala, O.; Matejka, V. M.; Mrazkova, P.; Bajciova, V.; Sedlackova, E.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Czech Registery of Neuroendocrine Neoplasms (NEN)

Pancreas
2014 | Journal article
WOSUID:

WOS:000333166800040
Contributors: Barkmanova, Jaroslava; Sedlackova, Eva; Honova, Hana; Louthan, Oldrich; Vitek, Pavel; Novak, Jiri; Muzik, Jan
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide Autogel/Depot Shows Antitumor Effects in Patients with Metastatic Enteropancreatic NETs: Results of the Clarinet Extension Study

Endocrine Reviews
2014 | Journal article
WOSUID:

WOS:000209805108094
Contributors: Caplin, Martyn E.; Ruszniewski, Philippe; Pavel, Marianne Ellen; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiota, Guillaume; Wall, Lucy; Rindi, Guido et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide Autogel/Depot Shows Antitumor Effects in Patients with Metastatic Enteropancreatic NETs: Results of the Clarinet Extension Study

Endocrine Reviews
2014 | Journal article
WOSUID:

WOS:000209805108095
Contributors: Caplin, Martyn E.; Ruszniewski, Philippe; Pavel, Marianne Ellen; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wall, Lucy; Rindi, Guido et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

New England Journal of Medicine
2014 | Journal article
DOI: 10.1056/NEJMoa1316158
EID:

2-s2.0-84904253184
Contributors: Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L. et al.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier
grade
Preferred source (of 2)‎

Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study

Neuroendocrinology
2014 | Journal article
WOSUID:

WOS:000343640100143
Contributors: Caplin, M.; Ruszniewski, P.; Pavel, M.; Cwikla, J.; Phan, A.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wall, L.; Rindi, G. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.

Journal of Clinical Oncology
2014 | Journal article
WOSUID:

WOS:000358613203270
Contributors: Caplin, Martyn E.; Ruszniewski, Philippe B.; Pavel, Marianne E.; Cwikla, Jaroslaw B.; Phan, Alexandria T.; Raderer, Markus; Sedlackova, Eva; Cadiot, Guillaume; Wall, Lucy R.; Rindi, Guido et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

The Neuroendocrine Tumor in Choroid: An Unusual Metastatic Location (Clinical Case Report)

Neuroendocrinology
2014 | Journal article
WOSUID:

WOS:000343640100206
Contributors: Barkmanova, J.; Sedlackova, E.; Glezgova, J.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)

European Journal of Cancer
2013 | Journal article
WOSUID:

WOS:000209470600008
Contributors: Caplin, M.; Ruszniewski, P.; Pavel, M.; Cwikla, J.; Phan, A.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Wall, L.; Rindi, G. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Lancet
2013 | Journal article
DOI: 10.1016/S0140-6736(12)61963-1
WOSUID:

WOS:000316060600030
Contributors: Davies, Christina; Pan, Hongchao; Godwin, Jon; Gray, Richard; Arriagada, Rodrigo; Raina, Vinod; Abraham, Mirta; Medeiros Alencar, Victor Hugo; Badran, Atef; Bonfill, Xavier et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Registry of Neuroendocrine Tumors (NET) in Czech Republic after three years of data collection | Registr neuroendokrinních nádorů (NET) v ČR po třech letech sběru dat

Klinicka Onkologie
2013 | Journal article
EID:

2-s2.0-84882751237
Contributors: Vítek, P.; Strenková, J.; Sedláčková, E.; Barkmanová, J.; Mužík, J.; Louthan, O.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier

[Colorectal carcinoma at the 1st Surgical Clinic in Prague]. | Kolorektální karcinom na I. chirurgické klinice VFN praha.

Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
2012 | Journal article
EID:

2-s2.0-84865383221
Contributors: Frýba, V.; Frasko, R.; Hoskovec, D.; Krska, Z.; Schmidt, D.; Sedlácková, E.
Source: Self-asserted source
Eva Sedlackova via Scopus - Elsevier

Czech Neuroendocrine Tumor Registry-28 Months Results

Neuroendocrinology
2012 | Journal article
WOSUID:

WOS:000308135300055
Contributors: Barkmanova, J.; Honova, H.; Louthan, O.; Sedlackova, E.; Novak, J.; Sachlova, M.; Vitek, P.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Breast Cancer Research and Treatment
2012 | Journal article
DOI: 10.1007/s10549-011-1741-6
WOSUID:

WOS:000298006300030
Contributors: Chirgwin, Jacquie; Sun, Zhuoxin; Smith, Ian; Price, Karen N.; Thuerlimann, Beat; Ejlertsen, Bent; Bonnefoi, Herve; Regan, Meredith M.; Goldhirsch, Aron; Coates, Alan S. et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

Lancet Oncology
2011 | Journal article
DOI: 10.1016/S1470-2045(11)70270-4
WOSUID:

WOS:000296581400019
Contributors: Regan, Meredith M.; Neven, Patrick; Giobbie-Hurder, Anita; Goldhirsch, Aron; Ejlertsen, Bent; Mauriac, Louis; Forbes, John F.; Smith, Ian; Lang, Istvan; Wardley, Andrew et al.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

Czech Neuroendocrine Registry - First Results

Neuroendocrinology
2011 | Journal article
WOSUID:

WOS:000297638900048
Contributors: Barkmanova, J.; Novak, J.; Vitek, P.; Sedlackova, E.; Honova, H.; Louthan, O.
Source: Self-asserted source
Eva Sedlackova via ResearcherID

LONG-TERM CONTROL OF BRAIN METASTASES IN BREAST CANCER PATIENTS BY LAPATINIB

Breast
2011 | Journal article
WOSUID:

WOS:000311082400071
Contributors: Tesarova, Petra; Sedlackova, Eva; Petrakova, Katarina; Palacova, Marketa; Grell, Peter
Source: Self-asserted source
Eva Sedlackova via ResearcherID
Items per page:
Page 1 of 2
How many people are using ORCID?